NO941422L - - Google Patents

Info

Publication number
NO941422L
NO941422L NO941422A NO941422A NO941422L NO 941422 L NO941422 L NO 941422L NO 941422 A NO941422 A NO 941422A NO 941422 A NO941422 A NO 941422A NO 941422 L NO941422 L NO 941422L
Authority
NO
Norway
Prior art keywords
immunogen
disclosed
isolated antibody
antibody immunoreactive
immunoreactive
Prior art date
Application number
NO941422A
Other languages
English (en)
Norwegian (no)
Other versions
NO317625B1 (no
NO941422D0 (no
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO941422(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO941422D0 publication Critical patent/NO941422D0/no
Publication of NO941422L publication Critical patent/NO941422L/no
Publication of NO317625B1 publication Critical patent/NO317625B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19941422A 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat. NO317625B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
NO941422D0 NO941422D0 (no) 1994-04-19
NO941422L true NO941422L (ref) 1994-06-27
NO317625B1 NO317625B1 (no) 2004-11-29

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Country Status (12)

Country Link
EP (2) EP0667901B2 (ref)
JP (2) JP3308534B2 (ref)
KR (1) KR100283541B1 (ref)
AT (2) ATE274055T1 (ref)
AU (1) AU661360B2 (ref)
CA (2) CA2121798C (ref)
DE (2) DE69233051T2 (ref)
DK (3) DK0822199T3 (ref)
ES (2) ES2227513T5 (ref)
FI (2) FI116850B (ref)
NO (2) NO317625B1 (ref)
WO (1) WO1993008207A1 (ref)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
CA2153806C (en) * 1993-01-22 2005-11-08 Melanie K. Spriggs Detection and treatment of mutations in a cd40 ligand gene
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
IL110852A (en) * 1993-09-02 1999-05-09 Dartmouth College Methods of prolonged suppression of humoral activity
ES2143553T3 (es) 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DK0751781T3 (da) * 1993-12-23 2004-08-09 Immunex Corp Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
EP0763057B1 (en) 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for proliferating and differentiating b cells, and uses thereof
FI973484A7 (fi) * 1995-03-01 1997-10-24 Immunex Corp Menetelmä immuunivasteen stimuloimiseksi
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
NZ311335A (en) * 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
DE69630120T2 (de) * 1995-06-22 2004-04-08 Biogen, Inc., Cambridge Kristalle von fragmenten von cd40-liganden und deren verwendung
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU3570797A (en) * 1996-06-14 1998-01-07 University Of Washington Absorption-enhanced differential extraction device
IL127912A0 (en) * 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DK2009025T3 (da) 1998-05-14 2011-11-14 Immunex Corp Fremgangsmåde til hæmning af osteoklast-aktivitet
DK2319928T3 (da) * 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP1173589A1 (en) * 1999-04-16 2002-01-23 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CA2424296A1 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
CN103232539B (zh) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1594955B1 (en) 2003-02-14 2012-04-11 Biogen Idec MA Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
CA2577125C (en) 2004-10-07 2016-01-12 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
TWI548747B (zh) 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
MY188753A (en) 2006-09-18 2021-12-29 Univ Arkansas Compositions and methods of enhancing immune responses
EP2197911A2 (en) 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
JP2011502165A (ja) 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
EP2214701B1 (en) 2007-11-01 2016-08-03 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria
AU2009206089B2 (en) 2008-01-15 2014-08-28 Abbvie Inc. Improved mammalian expression vectors and uses thereof
NO2501822T3 (ref) 2009-11-17 2018-01-13
HUE037157T2 (hu) 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
PT2579901T (pt) 2010-06-09 2019-11-05 Univ Arkansas Vacina e métodos para reduzir infeção por campylobacter
MY173328A (en) 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014152508A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
WO2017197098A1 (en) 2016-05-11 2017-11-16 Amgen Inc. Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
MY207687A (en) 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
KR20190124247A (ko) * 2017-02-27 2019-11-04 샤턱 랩스 인코포레이티드 Csf1r-기반 키메라 단백질

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
ES2227513T3 (es) 2005-04-01
AU3122693A (en) 1993-05-21
ES2198025T3 (es) 2004-01-16
NO320073B1 (no) 2005-10-17
FI981765L (fi) 1998-08-17
ATE274055T1 (de) 2004-09-15
FI116828B (fi) 2006-03-15
JPH10150994A (ja) 1998-06-09
WO1993008207A1 (en) 1993-04-29
JP2877788B2 (ja) 1999-03-31
KR100283541B1 (ko) 2001-03-02
EP0897983B1 (en) 2003-05-07
CA2312667C (en) 2002-11-19
EP0897983A2 (en) 1999-02-24
FI116850B (fi) 2006-03-15
EP0667901B2 (en) 2008-10-15
ATE239790T1 (de) 2003-05-15
EP0667901B1 (en) 2004-08-18
DE69233402T3 (de) 2009-06-25
FI981765A0 (fi) 1998-08-17
EP0667901A4 (en) 1995-06-22
DK0822199T3 (da) 2004-12-27
DE69233051D1 (de) 2003-06-12
DE69233402T2 (de) 2005-09-15
EP0667901A1 (en) 1995-08-23
CA2121798A1 (en) 1993-04-29
NO317625B1 (no) 2004-11-29
JPH07504083A (ja) 1995-05-11
FI941837A0 (fi) 1994-04-20
DK0897983T3 (da) 2003-08-11
CA2121798C (en) 2007-07-24
DE69233402D1 (de) 2004-09-23
FI941837L (fi) 1994-05-30
NO941422D0 (no) 1994-04-19
AU661360B2 (en) 1995-07-20
DK0667901T4 (da) 2008-11-10
DE69233051T2 (de) 2004-03-11
ES2227513T5 (es) 2009-04-01
NO980030L (no) 1998-01-05
EP0897983A3 (en) 1999-03-17
NO980030D0 (no) 1998-01-05
HK1019343A1 (en) 2000-02-03
JP3308534B2 (ja) 2002-07-29
DK0667901T3 (da) 2004-12-27
CA2312667A1 (en) 1993-04-29

Similar Documents

Publication Publication Date Title
NO941422L (ref)
GB2216256B (en) Optical encoder.
GB2222695B (en) Optical seeker with rosette scanning
AU5567990A (en) Rectified intraocular lens
EP0340779A3 (en) Optical quantum interference device
DE68916079D1 (de) Intraokulare Linse.
HU896517D0 (en) Optical transistor
EP0469853A3 (en) Light guide
AU586607B2 (en) Device for scanning a radiation-reflecting information surface with optical radiation
EP0507213A3 (en) Light transmitter
TW198026B (ref)
DE68917796D1 (de) Intraokulare Linse.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
BR8902568A (pt) Freio mecanico com ajuste automatico
DE69104049D1 (de) Mechanisch betätigte bremse mit automatischer justierung.
IT223115Z2 (it) Bruciatore a "rampete" con combustione cosiddetta iperstechiometrica
AU6861691A (en) Valve guide relining sleeve
GB9102177D0 (en) Photo diode
AU1205192A (en) Novel thyroid antigen
CA65789S (en) Handle for adjusting the position of a light
AU657865B2 (en) Light emitting diode scanner
KR890020199U (ko) 팩시밀리의 자동 급지장치
CS909588A1 (en) Connection for control valve's extreme positions automatic scanning
NO894118D0 (no) Fremgangsmaate for regulering av en tresliper.
GR880100752A (ref)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees